KQ | Jotup

4BY4's Pioneering AI Research Elevates Image Enhancement, Published in Prestigious Journal, Scientific Reports

Retrieved on:

Thursday, January 4, 2024

KQ, Research, PCT, Image, Patent, Scientific Reports, Creativity, Nature Portfolio, CCTV, Network, Science, Television

The paper, authored by the firm's in-house AI research powerhouse, Pixell Lab, delves into an advanced AI model for image enhancement, setting a new standard in the realm of visual technology.

Key Points:

The paper, authored by the firm's in-house AI research powerhouse, Pixell Lab, delves into an advanced AI model for image enhancement, setting a new standard in the realm of visual technology.
Published in Scientific Reports, a peer-reviewed journal by Nature Portfolio, the paper exemplifies the rigor and excellence of the research, aligning with the highest standards of scientific inquiry.
Pixell Lab's latest research tackles the complexities of images taken in environments with extreme lighting conditions, presenting a paradigm-shifting method to improve image quality.
The inclusion of our paper in Scientific Reports further validates the creativity and ingenuity of our image preprocessing methods."

4by4's 'Pixell AI' Solution Clinches Honors at CES 2024 Innovation Awards

Retrieved on:

Thursday, November 16, 2023

SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ -- Content AI solution company 4by4(KRX,389140 KQ), led by CEO Junho Yun, proudly announces the prestigious recognition of its cutting-edge AI solution, 'Pixell AI', at the CES 2024 Innovation Awards.

Key Points:

SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ -- Content AI solution company 4by4(KRX,389140 KQ), led by CEO Junho Yun, proudly announces the prestigious recognition of its cutting-edge AI solution, 'Pixell AI', at the CES 2024 Innovation Awards.
The CES Innovation Awards, organized by the Consumer Technology Association (CTA) as part of the renowned CES (The International Consumer Electronics Show) held annually in Las Vegas, spotlight innovative technologies and products that promise to shape the future.
The CES Innovation Award for 4by4 is reported to be an honor not only for the innovation in Pixell's technology but also for its marketability in the relevant industry.
In addition to the Innovation Awards, 4by4 has confirmed its participation in CES 2024, the world's largest IT and consumer electronics exhibition, scheduled for January in Las Vegas.

MAXST, expanded application of AR glasses through global technological cooperation with EPSON

Retrieved on:

Tuesday, May 16, 2023

KRX, Augmented reality, KQ, Epson, Lindsay Maxsted, Smartglasses, Computer, Environment, SDK, AR, Safety, Calibration, Television

With the recent release of version 6.0, MAXST's AR SDK has expanded the scope of application of AR technology to Epson's smart glasses, as well as RealWear and Nreal smart glasses.

Key Points:

With the recent release of version 6.0, MAXST's AR SDK has expanded the scope of application of AR technology to Epson's smart glasses, as well as RealWear and Nreal smart glasses.
This is the result of continuous technical cooperation between MAXST and Epson in the field of AR.
Through this collaboration, MAXST's AR development solution (MAXST AR SDK) has been applied to Epson's new Moverio smart glasses (model name: BT-45CS), enabling them to provide a high-quality AR experience.
MAXST optimized their AR engine for Epson's glasses to improve the precise target tracking capabilities of their smart glasses.

Steve Gorman, Founding Member of The Black Crowes, Heads to the Twin Cities as Morning Host for Cumulus Media’s Classic Rock Station, KQRS-FM

Retrieved on:

Monday, January 9, 2023

Gorman will join the established KQ Morning Show with co-hosts Brian Zepp, Tony Lee, and Candice Wheeler.

Key Points:

Gorman will join the established KQ Morning Show with co-hosts Brian Zepp, Tony Lee, and Candice Wheeler.
Gorman, the current host of live nighttime radio show Steve Gorman Rocks!
, syndicated by Cumulus Media’s Westwood One, will relocate to the Twin Cities.
After leaving the Black Crowes in 2014, Gorman penned his memoir, “Hard to Handle: The Life and Death of The Black Crowes”.

Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era

Retrieved on:

Thursday, February 24, 2022

This new assay is optimized for the 'living with COVID-19' era, where mass, swift and cost-efficient testing is vital.

Key Points:

This new assay is optimized for the 'living with COVID-19' era, where mass, swift and cost-efficient testing is vital.
Seegene advanced the isothermal amplification method by utilizing its AI-based assay design system, to specifically target the genes of SARS-CoV-2.
By combining such method and Seegene's applied TOCE technology, AllplexSARS-CoV-2 fast MDx Assay delivers highly accurate results within 30 minutes.
Greater Testing Capacity: Fasterturnaround times lead to greater lab testing capacity of up to five times with existing Seegene's PCR instruments.

Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era

Retrieved on:

Thursday, February 24, 2022

PCR, COVID-19, Efficiency, Gene, School, Marketing, Airport, Laboratory, Environment, KQ, Point-of-care testing, Severe acute respiratory syndrome coronavirus 2, Patient, Technology, CE, MDX, RT, Vaccine, Pharmaceutical industry

SEOUL, South Korea, Feb. 24, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today, announced the CE-IVD marking of its Allplex™ SARS-CoV-2 fast MDx Assay.

Key Points:

This new assay is optimized for the 'living with COVID-19' era, where mass, swift and cost-efficient testing is vital.
Seegene advanced the isothermal amplification method by utilizing its AI-based assay design system, to specifically target the genes of SARS-CoV-2.
By combining such method and Seegene's applied TOCE technology, AllplexSARS-CoV-2 fast MDx Assay delivers highly accurate results within 30 minutes.
Greater Testing Capacity: Fasterturnaround times lead to greater lab testing capacity of up to five times with existing Seegene's PCR instruments.

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Retrieved on:

Wednesday, January 19, 2022

PCR, Technology, IVD, CT, COVID-19, Polymerase chain reaction, MDX, RNA-dependent RNA polymerase, DPO, Multimedia, KQ, Marketing, Dual, Laboratory, Hospital, Pharmaceutical industry, Online shopping

Reduction of the turnaround time was attributable to two primary reasons: 1) the application of a novel enzyme developed by Seegene, which reduces PCR process time to half.

Key Points:

Reduction of the turnaround time was attributable to two primary reasons: 1) the application of a novel enzyme developed by Seegene, which reduces PCR process time to half.
2) Seegene's innovative extraction-free method, which can let Allplex SARS-CoV-2 Fast PCR Assay be available without the extraction of the sample preparation in PCR-based tests.
As such, the new assay lessens the amount of hands-on processing time required, allowing facilities to triple their testing capacity in the same hour.
"For the time being, we plan to target large-scale testing markets in more than 60 countries all across the globe.

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Retrieved on:

Wednesday, January 19, 2022

PCR, Technology, IVD, CT, COVID-19, Polymerase chain reaction, MDX, RNA-dependent RNA polymerase, DPO, KQ, Marketing, Dual, Laboratory, Hospital, Pharmaceutical industry

SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is expected to reduce the total turnaround time to a third and expand testing capacity up to 3 times for hospitals and laboratories without additional instruments or compromise on accuracy.

Key Points:

Reduction of the turnaround time was attributable to two primary reasons: 1) the application of a novel enzyme developed by Seegene, which reduces PCR process time to half.
2) Seegene's innovative extraction-free method, which can let Allplex SARS-CoV-2 Fast PCR Assay be available without the extraction of the sample preparation in PCR-based tests.
As such, the new assay lessens the amount of hands-on processing time required, allowing facilities to triple their testing capacity in the same hour.
"For the time being, we plan to target large-scale testing markets in more than 60 countries all across the globe.

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

Retrieved on:

Thursday, December 9, 2021

PCR, RT, COVID-19, Technology, Stealth, World Health Organization, RNA-dependent RNA polymerase, Multimedia, World, N501Y, Alpha-beta model, KQ, Severe acute respiratory syndrome coronavirus 2, WHO, Medical device, Vaccine

The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.

Key Points:

The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.
Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.
Immediately after the World Health Organization (WHO) announced a discovery of the Omicron variant, Seegene implemented its AI-based in-silico system to conclude this development within a week.
Today, Seegene is able to rapidly develop new tests ahead of emerging variants using the company's big data auto-surveillance in silico system.

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

Retrieved on:

Thursday, December 9, 2021

PCR, RT, COVID-19, Technology, Stealth, World Health Organization, Alpha, RNA-dependent RNA polymerase, World, N501Y, Alpha-beta model, KQ, Severe acute respiratory syndrome coronavirus 2, WHO, Medical device, Vaccine

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants. Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.

Key Points:

The new assay identifies positive COVID-19 cases and distinguishes between Alpha, Beta, Gamma, Delta, Omicron and its Stealth version.
The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.
Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.
Immediately after the World Health Organization (WHO) announced a discovery of the Omicron variant, Seegene implemented its AI-based in-silico system to conclude this development within a week.